• Explore /
  • Poster
  • / Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER.

Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER.

Abstract Video & Slides Poster

Authors

null

Robert J. Motzer

Memorial Sloan Kettering Cancer Center, New York, NY

Robert J. Motzer , Toni K. Choueiri , Thomas Powles , Mauricio Burotto , Maria Teresa Bourlon , James J Hsieh , Marco Maruzzo , Amishi Yogesh Shah , Cristina Suarez , Carlos H. Barrios , Martin Eduardo Richardet , Camillo Porta , Jeffrey C. Goh , Yoshihiko Tomita , Jens Bedke , Joshua Zhang , Burcin Simsek , Christian Scheffold , Saurabh Gupta , Andrea B. Apolo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03141177

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr 308)

DOI

10.1200/JCO.2021.39.6_suppl.308

Abstract #

308

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Thomas Powles

First Author: David Cella

First Author: Toni K. Choueiri

First Author: Philippe Barthelemy